Preservation solution for lung transplantation.
Despite the increasing success of lung transplantation as the mainstay therapeutic modality for end-stage lung disease, the 1-year survival rate after lung transplantation remains 80% and primary graft dysfunction (PGD) accounts for 30% of mortality. Ischemia-reperfusion injury has been identified as one of the main causes of PGD, and thus significant efforts have been made to optimize the methods for lung preservation in an attempt to minimize lung injury during the period of ischemia. The composition of the lung preservation solution used in the pulmonary artery flush has been considered to be the key to successful lung preservation, and many lung transplant programs have been shifting the use of the preservation solution from the intracellular fluid type to the extracellular fluid type because of preferable posttransplant lung function with the latter. This review summarizes the experimental and clinical studies on lung preservation, particularly focusing attention on the preservation solution being employed for clinical lung transplantation.
Okada
Yoshinori
Y
Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Aobaku, Sendai, Japan. yokada@idac.tohoku.ac.jp
Kondo
Takashi
T
D000818:Animals; D006085:Graft Survival; D006801:Humans; D016040:Lung Transplantation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D019188:Organ Preservation Solutions / Q000009:adverse effects / Q000627:therapeutic use*; D010477:Perfusion; D055031:Primary Graft Dysfunction / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D015427:Reperfusion Injury / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D013997:Time Factors; D014021:Tissue Preservation; D016896:Treatment Outcome
D019188:Organ Preservation Solutions